In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies.

The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation.

In the webinar in the series of summer educational webinars FreeMind experts will discuss the latest trends at the NIH and the new available funding opportunities with respect to medical devices.

Assembling a budget for your grant is typically the last item to be addressed. Reason being that the figures you are suggesting must reflect the work you are proposing to complete.

That said, simply stating the cost per item is hardly enough, and a properly constructed justification is mandatory and weighs heavily on approval of your budget. When comprising the budget one must ensure an accurate completion of the document while adhering to NIH guidelines and stipulations. Items such as indirect costs, sub-contractors, sub-awards, salaries, and even travel expenses must be completed correctly. This becomes increasingly difficult when large and complex applications have several budgets feeding into one.

NINDS has just issued a number of funding opportunities covering separately the development of biologics, small molecules and devices in a cooperative manner with the issuing institute (U-Mechanism). This serves a major paradigm shift in NINDS funding.

Further, within the non-dilutive funding space one can find pockets of money in the billions of dollars directed at unmet medical needs related to CNS/PNS ailments. The scope of funding support covers much of the R&D cycle from proof of concept to late stage clinical.

NIH alone awards roughly $5.8B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle with an emphasis on pre-clinical work, and may cover clinical stage activities as well.

In this webinar in the series of summer educational webinars, FreeMind experts discuss key cancer related opportunities, mainly within the National Cancer Institute (NCI), that are available for Life Science organizations.

Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc.
In this presentation we will provide insight into the non-dilutive funding landscape with an emphasis on the NIH, Department of Defense and other government agencies. FreeMind experts will describe the various pockets of money available for non-US applicants, potential for funding, and means to maximize chances for award.

Every year NIH alone awards over $120,000,000 via R’-Mechanisms, among them the RO1 or R21. In order to maximize your funding potential all sources of funding must be considered including the less traditional sources.

R21s aim to fund very early stage proof of concept type programs of up to 2 years at about $300,000, whereas RO1s are more suitable for longer programs of up to 5 years, totaling some $3,000,000.

In this webinar FreeMind experts will share insight into alternatives to the classic SBIR/STTR mechanisms. We will discuss methodology for establishing both responsiveness as well as competitiveness and how to increase chances for award.

The National Institute of Allergy and Infectious Diseases (NIAID) awards close to $6,000,000,000 annually. Taking into account activities by DTRA, DARPA, US Army, BARDA, etc. this is a funding force no one in the field can afford to ignore.

Date: Wednesday, July 16
Time: 12:00 – 1:00 PM, EDT

In this first webinar in the series of summer educational webinars we will discuss:

  • Sources of Biodefense and Infectious Diseases funding – DOD (USAMRMC, DTRA, DARPA), NIH, BARDA etc.
  • Specific funding opportunities
  • Rapidly approaching deadlines
  • Major challenges
  • Keys to maximizing chances for award

Weekly Online Educational Webinars – July 2nd – August 27th, 2014

FreeMind’s knowledgeable team of expert grant writers share their wisdom on how to maximize chances for award.

Participation is FREE of Charge, Registration is Required

Date Title
July 16th Biodefense and Infectious Diseases Non-dilutive Funding
July 23rd RO1 and R21s for Companies
July 30th Non-Dilutive funding for Non-US applicants
August 6th Cancer Non-dilutive Funding
August 13th CNS/PNS Related Non-Dilutive Funding Opportunities
August 20th Details of a Detailed Budget; Accurately Constructed and well Justified
August 27th Medical Device Non-Dilutive Funding: Trends & Opportunities
September 3rd SBIR/STTR
September 10th Registration ins and outs; smooth sailing to an error free submission

 

Register

Registration is a multi-step process that can take 8 weeks or more and MUST be completed before the submission deadline. Organizations must be registered with the System for Award Management (SAM), Grants.gov and eRA Commons.

The registration process is not sequential. As soon as an organization has obtained its DUNS number, it can begin registering with SAM and then Grants.gov and eRA Commons.

All too often organizations struggle with the registration process. This leads to rejected applications and frustration.

In this webinar, Ms. Noa Larroche provided a step by step guide to the registration process.

Specifically Ms. Larroche cover:
-How to obtain a DUNS number
-Registering with grants.gov, SAM, eRA Commons
-Generating other acronyms such as: AOR, eBiz POC, TIN, EIN
-Important Tips
-Trouble Shooting
-Successful submission!

In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies.

The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation.

In the upcoming webinar in the series of summer educational webinars, FreeMind’s VP, Ayal Ronen, will discuss the latest trends at the NIH and the new available funding opportunities with respect to medical devices.

Specifically Mr. Ronen will cover:

  • Trends in medical device non-dilutive funding
  • Cross section analysis of different opportunities available
  • The NIBIB – The National Institute of Biomedical Imaging and Bioengineering
  • Challenges
  • How to maximize chances for success